Expression and function of angiopoietin-1 in breast cancer by Hayes, A J et al.
Tumours undergo a critical transition from an avascular to a
vascular stage by invoking an angiogenic response from host
vasculature (Folkman, 1971). To do this the cancer cells elaborate
growth factors and cytokines that act upon the surrounding
endothelial cells (Hanahan and Folkman, 1996) which induce
vascular sprouting and new blood vessel formation. Certain of
these factors, such as fibroblast growth factor-1 (FGF1), may have
both paracrine and autocrine effects on tumour growth because 
of the distribution of their receptors on tumour cells and other
stromal cells, as well as endothelial cells (Lehtola et al, 1992).
Other factors such as vascular endothelial cell growth factor
(VEGF), target only endothelial cells because the expression of
their receptors is restricted to endothelial cells (de Vries et al,
1992; Terman et al, 1992).
Angiopoietin-1 (Ang1) is a recently described growth factor
whose target cells are also endothelial cells, because the expres-
sion of the receptor, Tie2 (Tek), is restricted essentially to endo-
thelial cells (Dumont et al, 1993; Maisonpierre et al, 1993).
Transgenic animal studies indicate that Ang1 is central to
embryonic vascular development (Sato et al, 1995; Suri et al,
1996; 1998; Maisonpierre et al, 1997; Thurston et al, 1999). Ang1
knock-out animals die in utero because of specific vascular
deficits. These include failure of the primitive capillary plexus to
branch appropriately and failure of the endothelial cells to form
stable associations with surrounding basement membranes and
pericytes. Knock-out of the Tie2 gene gave rise to essentially the
same phenotype. Overexpression of Ang1 in the skin of transgenic
animals causes an increase in the number, size and branching
complexity of dermal vessels. In vitro, Ang1 protects against
endothelial cell apoptosis, stabilizes endothelial tubules and
induces vascular sprouting and tubule formation in collagen
(Koblizek et al, 1998; Hayes et al, 1999; Holash et al, 1999;
Papapetropoulos et al, 1999; Thurston et al, 1999). In vivo Ang1
synergizes with VEGF to promote corneal neovascularization
(Asahara et al, 1998). Together these findings all suggest that
Ang1 acts physiologically as an angiogenic promoter in the devel-
oping vascular system, in a coordinated process involving other
angiogenic factors such as VEGF (Shalaby et al, 1995; Carmeliet
et al, 1996; Ferrara et al, 1996).
We investigated whether Ang1 would serve an analogous func-
tion in tumours by promoting vascularization. Ang1 expression
levels were assessed in breast cancer cell lines and in breast
cancer specimens. The gene was then overexpressed in a breast
cancer cell line (MCF-7) by itself or together with FGF1. Our data
indicate that Ang1 is rarely expressed by breast cancer cells in
clinical samples. Moreover, Ang1 not only fails to enhance
xenograft tumour growth in the MCF-7 tumour model, but appears
to act in inhibitory capacity in this model. Possible reasons for the
apparently contradictory roles for Ang1 in physiological and
tumour angiogenesis are discussed.
METHODS
Cell culture
The MCPX cell line is a sub-line of ML-20 cells which were
derived from MCF-7 cells by transfection with β -galactosidase
(lacZ) (Kurebayashi et al, 1993; McLeskey et al, 1993; 1998). The
α 18 cells, referred to as Clone 18 previously, were derived from
ML-20 cells by transfection with FGF1 (Zhang et al, 1997). Cell
lines were cultured in 5% FBS, IMEM, 4 mM glutamine
(Biofluids, Rockville MA, USA).
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Frozen sections (5 µ m) were immuno-stained with monoclonal
antibodies to Tie2 (a gift from Dr Kevin Peters, Procter and
Gamble, Cincinnati OH, USA), and to von Willebrand factor
(Boehringer Mannheim, Indianapolis IN, USA). Sections were
fixed in acetone at –20° C for 10 min, incubated in 0.3% hydrogen
peroxide in methanol, blocked in 5% BSA (Sigma, Milwaukee
WI, USA) 2.5% normal horse serum (Vector Labs, Burlingame
CA, USA) in PBS then incubated with antibody in blocking solu-
tion. Sections were washed in PBS, then incubated for 1 h with a
1:5000 dilution of a biotinylated polyclonal antibody against
mouse IgG and developed using a Vector ABC kit (Vector Labs),
then counter-staining with haematoxylin.
Laser-capture microdissection
Frozen tumour samples and adjacent normal breast tissue were
used for laser-capture microdissection using previously
described methods (Emmert-Buck et al, 1996), utilizing a Pixcell
laser-capture microdissection system (Arcturus Engineering,
Mountain View CA, USA). Clinical sections, immuno-stained
for Tie2 and vWF, were examined to identify areas of high
microvessel density. Microvessel counting was performed using
standard techniques (Weidner, 1995). Unmounted serial sections
stained with eosin, or with haematoxylin and eosin, were then
examined to locate parallel areas. A Capsure Cap (Arcturus
Engineering) was then placed onto the section over a 30 µ m
diameter capture area comprising either tumour cells in areas of
high microvessel density, or epithelial cells in normal breast
acini. Upon laser capture, cells in 50 areas were transferred into a
0.5 ml Eppendorf vial, yielding 500–1000 cells per sample. Total
RNA was retrieved using a Micro RNA Isolation kit (Stratagene,
La Jolla CA, USA) and RNA corresponding to that collected
from approximately 250 cells was used as a template for subse-
quent RT-PCR.
Reverse transcriptase-linked polymerase chain
reaction (RT-PCR)
The primer sequences for Ang1 are: 5′ -CAACTGGAGC TGATG-
GACAC A-3′ (sense) and 5′ -ACTGCCTCTG ACTGGTAATG G-
3′ (antisense) and span base pairs 1060–1420 of Ang1 mRNA. 
The primer sequences for VEGF are 5′ -GCCTTGCCTT
GCTGCTCTAC-3′ (sense) and 5′ -AATGCTTTCT CCGCT-
CTGA-3′ (antisense) spanning base pairs 48–473. The primer
sequences for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) are 5′ -AAGGTGAAGG TCGGAGTCAA CG-3′
(sense) and 5′ -TGGTGGTGCA GGAGGCATTG C-3′ (antisense)
spanning base pairs 40–496. The GAPDH primers span introns
1–5 in the genomic sequence. Total RNA collected from a panel 
of breast cancer cell lines was supplied by Dr Anke Schultke,
Lombardi Cancer Center and 0.1 µ g was used as a template. RT-
PCR analysis was performed using reagents supplied in a
GeneAmp RNA PCR core kit (Perkin Elmer, Wellesley MA,
USA), with a Perkin Elmer GeneAmp 2400 PCR system. The
DNA was transferred onto a Nytran nylon membrane (Schleicher
& Schuell, Keene NH, USA). Southern hybridization was
performed using oligonucleotide nested primers end-labelled with
γ -32P-dATP (Amersham, Piscataway NJ, USA). The sequences 
of the nested primers were: for Ang1, 5′ -AGACTGTGCA
TGTATATC-3′ ; for VEGF, 5′ -CAATGACGAG GGCCTGGAGT-
3′ ; and for GAPDH, 5′ -GTCTTCACCA CCATGGAGAA-3′ .
Transfection of the cancer cells with Ang1
The plasmid, jFE14/Ang1 is derived from the pSRα plasmid
which contains an HTLV-1 promoter (Takebe et al, 1988). Full-
length human Ang1 cDNA was cloned into this plasmid at two
BstX 1 sites. Co-transfection was performed with the pcDNA3.1
Zeo plasmid (Invitrogen) which confers resistance to the anti-
biotic Zeocin (250 mg ml–1), using Lipofectamine Plus reagent
(GibcoBRL, Rockville MD, USA).
Western slot blot analysis
Conditioned media were mixed (1:1) with DPBS containing
0.01% CHAPS (Sigma) and loaded in duplicate onto a Bio-dot SF
slot blot apparatus (Bio-Rad, Hercules CA, USA), with Hybond
ECL nitrocellulose membrane. After blocking, the membrane was
incubated a rabbit polyclonal antibody against Ang1, developed at
Regeneron Pharmaceuticals (Tarrytown NY, USA), in TBS, 0.1%
Tween-20, 1.25% BSA, washed, then incubated with a horseradish
peroxidase-conjugated anti-rabbit IgG antibody and developed
using ECL chemiluminescence (Amersham)
Tie2 phosphorylation assay
Tie2-transfected fibroblasts were treated for 5 min with condi-
tioned media then immunoprecipitated for phosphorylated Tie-2 as
described previously (Maisonpierre et al, 1997). Cells were lysed
in RIPA buffer containing 1% Nonidet P40, 0.5% sodium deoxy-
cholate, 0.1% SDS plus protease- and phosphatase-inhibitors. Tie2
was immunoprecipitated using an anti-myc monoclonal antibody,
9E10 (Sigma) and protein G-Sepharose beads. Samples were
analysed by standard Western blotting protocols, including resolu-
tion by reducing SDS-PAGE and electrotransfer to PVDF
membranes. The amount of total Tie2 receptor and auto-
phosphorylated Tie2 receptor was detected, respectively, by
incubating replicate membranes with 9E10 or with the anti-
phosphotyrosine-specific monoclonal antibody, 4G10 (Upstate
Biotechnology, Lake Placid NY, USA) visualized with a HRP-
conjugated secondary antibody.
BIAcore analysis
Conditioned media were analysed for Ang1 with a BIAcore
biosenser (Pharmacia, Piscataway NJ, USA) utilizing a CM5
BIAcore chip surface that had been covalently coupled with
recombinant soluble Tie2-Fc as described previously (Davis et al,
1996). To control for the specificity of ligand binding, media were
pre-incubated with 20 µ g ml–1 of excess soluble Tie2-Fc or two
irrelevant soluble receptors. Only soluble Tie2-Fc competed for
Ang1 binding to the chip surface.
Northern blotting analysis for FGF1 expression
An FGF1 cDNA probe was labelled with α 32P-dCTP (Amersham)
using a Random-Primers DNA labelling system (GibcoBRL) and
used in Northern analyses of total RNA as described previously
(Zhang et al, 1997).
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NCR (nu/nu) athymic female 4–6-week-old mice (Taconic Farms
Inc, Germantown NY, USA) were supplemented with subcuta-
neously embedded 0.72 mg oestrogen pellets then inoculated
subcutaneously in the mammary fat pads with 5 × 106 cells in 
0.2 ml IMEM. Tumour volumes (length × width × height) were
measured two times a week in a blinded manner.
Statistical analyses
Generalized linear mixed effects models were used to estimate
tumour growth rates. The analysis was performed using SAS
PROC MIXED procedure according to SAS/STAT User’s Guide
(SAS Institute Inc, Cary NC, USA). Plots of tumour sizes vs time
for the MPCX tumour growth data revealed an exponential growth
pattern. Plots of tumour size vs time for the α 18 tumour growth
data indicated the growth rate in some cell lines was negative to
some time-points and then became positive, suggesting that an
overall growth rate was not appropriate to summarize the growth
pattern. For these data, we described the growth pattern for each
cell line at certain time-points and compared the growth rates at
these time-points using repeated analysis of variance.
RESULTS
Ang1 expression in breast cancer cell lines
We analysed Ang1 expression in a panel of 19 breast cancer cell
lines by RT-PCR analysis (Figure 1). Ang1 transfected CHO cells
were used as a positive control. PCR products were subjected to
agarose gel electrophoresis and visualized with ethidium bromide.
To exclude non-specific PCR amplifications, the PCR products
were then subjected to Southern blotting analysis with a radio-
labelled ‘nested’ Ang1 primer that corresponded to a sequence of
Ang1 cDNA between PCR primers. A positive signal for Ang1
was identified from RNA isolated from nine out of the 19 breast
cancer cell lines.
Low Ang1 expression in human breast cancer clinical
specimens
We then determined whether breast cancer cells express Ang1
under clinical conditions. We utilized laser-capture microdissec-
tion and subsequent RT-PCR on the RNA isolated from microdis-
sected specimens for this analysis. This technique permitted the
isolation of a relatively homogeneous population of cancer cells
adjacent to tumour vessels, which expressed a high level of
the receptor Tie2 (Figure 2). It also involved amplification of the
mRNA signal, as our previous efforts to determine Ang1 expression
1156 AJ Hayes et al
British Journal of Cancer (2000) 83(9), 1154–1160 © 2000 Cancer Research Campaign
Ang-1
(Southern)
Ang 1
(361 bp)
GAPDH
(456 bp)
W
a
t
e
r
C
H
O
 
A
n
g
-
1
C
H
O
 
V
e
c
t
o
r
M
D
A
M
B
 
2
3
1
B
T
5
4
9
T
4
7
D
M
D
A
-
M
B
-
4
6
8
T
4
7
D
C
O
H
S
5
7
8
T
B
T
2
D
M
C
F
7
/
A
D
R
M
D
A
-
M
B
-
4
3
5
S
K
B
R
3
B
T
4
7
4
M
D
A
-
M
B
-
1
5
7
M
D
A
-
M
B
-
4
5
3
D
U
4
4
7
5
Z
R
7
5
3
0
M
D
A
-
M
B
-
3
6
1
M
D
A
-
M
B
-
1
3
4
M
C
F
-
1
0
A
M
C
F
-
7
M
C
F
-
7
 
R
A
S
Figure 1 RT-PCR analysis of breast cancer cell lines for Ang1 mRNA.
Positive and negative control cells were CHO cells transfected with Ang1
(CHO Ang1) or an empty vector (CHO Vector). The lower two panels show
RT-PCR products after agarose gel electrophoresis, visualized by ethidium
bromide staining. The top row is a Southern hybridization of the Ang1 
RT-PCR products with a 32P-labelled nested primer
A
B
C
Figure 2 Human breast cancer specimens before and after laser-capture
microdissection. (A) Frozen section of ductal carcinoma was immuno-stained
with a monoclonal antibody against Tie2: staining (arrow) indicates blood
vessels that express Tie-2. (B) Serial section (eosin staining) showing the
same ductule filled with breast cancer cells in which the cancer cells have
been outlined by a laser field (arrow) prior to microdissection. (C) The same
specimen as in B but subjected to microdissection; note the empty space left
by the breast cancer cells now capturedwith in situ hybridization experiment did not reveal any Ang1
signals in breast cancer specimens despite ample signals in control
samples of Ang1-transfected cancer cells (data not shown). After
reverse transcription of the mRNA from the microdissected cells,
the cDNA samples were analysed for Ang1 by Southern blotting
with a ‘nested’ oligonucleotide probe. VEGF mRNA, which is
abundant in tumours, was analysed as a positive control. Figure 3
shows the results of an analysis of six tumour specimens. Control
cells that expressed Ang1 display a clear signal for Ang1 which is
approximately equal to that seen for GAPDH, an internal control,
irrespective of whether the RNA was collected directly from cells
growing in tissue culture or from frozen sections of cell pellets.
In the majority of microdissection experiments no Ang1 signal
was seen even after prolonged exposure, while the GAPDH signal
was clearly demonstrated (Figure 3A). In contrast, similar analysis
of VEGF expression in the same six tumour samples yielded a
strong signal in five of six cases, confirming the abundance of this
angiogenic factor in tumours and the suitability of microdissection
as a method of analysis (Figure 3B).
Table 1 shows a summary of the results of Tie2 and Ang1
expression analysis of 11 normal and 23 malignant specimens.
Samples were informative for Ang1 expression only if a GAPDH
signal was visible after Southern hybridization. Although Tie2 
is clearly expressed on microvessels of tumours and correlates
closely to the expression of vWF (correlation coefficient 0.91), a
detectable Ang1 signal was identified only in three of 21 tumour
cases analysed and none of nine normal cases.
Transfection of Ang1 cDNA into breast cancer cell lines
results in the expression of high levels of biologically
active Ang1 in conditioned media
In order to determine the effect of elevated Ang1 levels on tumour
growth, we stably transfected Ang1 into two cell lines derived
from the oestrogen-dependent, poorly angiogenic and weakly
tumorigenic MCF-7 cells: the MPCX cells and the α 18 cells. The
MPCX cells, which were transfected with the β -galactosidase gene
(lacZ) for convenient detection, maintains essentially the same
growth characteristics to the MCF-7 cells, while the α 18 cells,
which were further transfected with FGF1, exhibited a greatly
increased tumorigenicity and an extreme form of the dysfunctional
vascular phenotype seen in xenograft tumours, with abundant
vessels that are dilated (Zhang et al, 1997).
Ang1 protein in the conditioned media of the transfected cells
was detected by Western slot blot analysis using a polyclonal
antibody against human Ang1 (Figure 4A). An estimation of the
amount of Ang1 was made by comparison with signals from an
Ang1 preparation of known concentration. The ability of the Ang1
protein to bind to Tie2 was determined by using a BIAcore
analyser, which also allowed a quantitative determination of the
concentration of Ang1 (Table 2). The Ang1 concentrations deter-
mined by these methods correlated closely. Furthermore, the
biological activity of Ang1 in the conditioned media was deter-
mined by measuring the ability of the conditioned media to induce
Tie2 tyrosine phosphorylation (Figure 4B). The extent of phos-
phorylation induced by conditioned media from the highest
expressing clones was equivalent to that produced by 200 ng of
recombinant Ang1, which gave rise to a maximum extent of phos-
phorylation of Tie2 on the cells. The α 18-derived cell lines were
further analysed for continued expression of FGF1 mRNA by
Northern analysis (Figure 4C). All of the FGF1 transfected cell
lines expressed high levels and equivalent amounts of FGF1
mRNA. In vitro mitogenesis assays were performed on all trans-
fected and parental cell lines prior to animal inoculation, to ensure
that the transfection procedure or the expression of Ang1 had not
altered the in vitro growth characteristics (data not shown). As
expected, Ang1 overexpression had no effect on the growth rates
of all the selected clones in cultures since MCF-7 cells do not
express the Tie2 receptor.
Inhibition of MCF-7 xenograft tumour growth by Ang1
overexpression
Three Ang1 expressing clones, as well as a pooled population
of empty vector transfected cells and the parental cells, were inocu-
lated into the mammary fat pads of athymic nude mice. The growth
rates of the xenograft tumours were monitored. The tumours were
retrieved at the end of the experiment and the expression of Ang1
confirmed by Northern blotting analysis (data not shown). Although
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Figure 3 Expression of Ang1 and VEGF in tumour specimens determined
by using laser-capture microdissection. (A) Detection of Ang1 expression in
six tumour specimens by RT-PCR and subsequent Southern analysis.
Controls are RNA isolated from Ang1 transfected cells growing in culture
(Ang1/TC) or microdissected from a section of a cell pellet (Ang1/LCM). 
(B) Detection of VEGF in the same cancer specimens by RT-PCR and
Southern analysis
Table 1 Summary of Ang1, Tie2, and vWF expression in clinical specimens.
Clinical specimens (nine grade 3 tumours, nine grade 2 tumours, three grade
1 tumours and 11 normal breast sections) were stained with monoclonal
antibodies to Tie2 and vWF. Positively staining vessels were counted
manually using standard protocols (Weidner, 1995). Densities (± SEM) refer
to number of vessels per 0.74 mm2 microscopy field at × 200 magnification.
Ang1 expression was analysed by laser-capture microdissection from cells
adjacent to the immuno-stained vessels. Specimens were considered
informative for Ang1 expression only if GAPDH was detectable
Sample Cases Number of Number of Cases Cases
stained for Tie-2 vWF informative with Ang1
Tie-2 and expressing expressing for Ang1 signal
vWF micro-vessels micro-vessels expression
per sample per sample
Normal 11 12 (± 2.7) 20 (± 4.6) 9 0
Tumour 23 35 (± 3.7) 44 (± 3.9) 21 3Ang1 overexpressing MPCX cells were able to grow xenograft
tumours, the growth rates of the transfected cells were decreased as
compared with the parental or vector control. A dramatic inhibitory
effect (P = 0.003) was observed with the clone MAng 184 that
expressed the most Ang1 (Figure 5A). The extent of rate-decrease
correlated reasonably well with the amount of Ang1 produced by
the transfected cells (Figure 5B and Table 2).
Similar experiments were carried out with the FGF1 and Ang1
co-transfected  α 18 cell lines. The growth of the xenograft
tumours of the Ang1 overexpressing cells was again found to be
much slower than that of the parental cells and the vector mock
transfected cells (Figure 6A). A statistically significant inhibi-
tion of tumour growth was observed with clones α Ang 18 and
α Ang 29 (P = 0.03). The dimensions of the tumours produced by
clone α Ang 14 were not statistically different from the parental
or vector controls. However, for clone α Ang 14 the recorded
tumour volume did not represent the actual volume of tumour
cells. This is because the majority of the volume of the
xenografts formed by this clone at the end of the assay was
caused by blood in a haemangectasic sac. In contrast, while the
parental and vector cells produced a haemangectasic sac initially,
this was replaced by a solid mass of tumour cells as the tumour
growth progressed (Zhang et al, 1997). We demonstrated this at
the end of the experiment by staining all of the xenografts with a
β -galactosidase substrate. This allowed for easy identification of
the tumour as blue cells (Figure 6B). A solid mass of cancer cells
had replaced the haemangectasic sac in the tumours produced 
by the parental α 18 cells (Figure 6B, right). In contrast, the
haemangectasic sac responsible for the large dimensions of
the α Ang 14 tumours was still not replaced by a tumour mass
at the end of the assay but consisted principally of blood (Figure
6B, left). On transection, it was demonstrated that the cancer
cells occupied a relatively small proportion of the tumour
volume (Figure 6B, centre) implying that the rate of tumour cell
growth was very much smaller than that recorded by measure-
ment of xenograft dimensions.
DISCUSSION
We tested the hypothesis whether Ang1 would serve a pro-angio-
genic role in the context of tumours, similar to its role suggested
for physiological neovascularization. We found that Ang1 expres-
sion is lacking from areas adjacent to tumour blood vessels in
human breast cancer despite abundant expression of Tie2 in these
vessels. In addition, overexpression of Ang1 did not enhance
xenograft growth and the majority of Ang1 transfected clones
demonstrated decreased growth rates. Our data demonstrate that
Ang1 may not function as a promoter of angiogenesis in breast
tumours. Moreover, the data suggests that it may act in an
inhibitory capacity in this model.
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Figure 4 Production of Ang1 by Ang1 transfected MPCX and α 18 cells. 
(A) Western slot blot analysis of Ang1 in the conditioned media. Duplicate
aliquots of COS cell conditioned media of known Ang1 concentration were
used as standards (upper panel). Five clones of the Ang1 transfected MPCX
cells and three clones of the Ang1 transfected α 18 cells were shown in
duplicate (lower panel), in comparison with the parental (P) and empty vector
transfected (V) cells. (B) Ang1 activity in the conditioned media was
determined for the ability to induce Tie2 tyrosine phosphorylation. NIH 3T3
cells overexpressing myc-tagged Tie2 were treated with the conditioned
media, then subjected to immuno-precipitation with an anti-myc antibody, and
Western blotting analysis with an anti-phosphotyrosine antibody (upper
panel). The cells were also treated with 200 ng ml–1 of Ang1 to provide a
positive control. A Western analysis with an antibody against the myc-tag as
a loading control (lower panel). (C) Northern blotting analysis of FGF1 in
RNA collected from Ang1 transfected α 18 cells. The internal control was 
β -actin FGF1
Table 2 Ang1 concentrations in the conditioned media of either vector
transfected or Ang1 transfected cells (BIAcore analysis)
Cell line Ang1
(ng ml–1)
MPCX Vector 0
MAng128 240
MAng166 160
MAng184 820
α 18 Vector 0
α Ang14 172
α Ang18 612
α Ang29 156These findings initially appear to be in contrast to transgenic
studies in which Ang1 was overexpressed locally in the skin of
developing mice. This overexpression of Ang1 induced remark-
able increases in vascularity in the skin of these transgenic animals
(Thurston, 1999). These seemingly contrary findings for Ang1
overexpression in transgenic animals and in our tumour models
suggest that the process of tumour vascularization may be dis-
similar to that seen in physiological settings. Physiological angio-
genesis occurs in the context of a number of angiogenic factors
and the expression of these factors is precisely coordinated both
temporally and spatially (Dumont et al, 1995). Tumours elaborate
a variety of angiogenic factors (Relf et al, 1997) and as a conse-
quence of the abundance of angiogenic influences in the tumour
micro-environment, the microvessel density in a tumour may be
very high, although many vessels are dysfunctional. This dysfunc-
tion is manifested by areas of tumour necrosis and tumour hypoxia
seen near to areas of increased microvessel density. The failure to
identify Ang1 expression in the breast cancer epithelial cells
suggests that Ang1, which is hypothesized to promote the ordered
expansion of the vascular tree physiologically, may not be a
pertinent angiogenic factor to the highly disordered tumour vascu-
lature.
The data from overexpression of Ang1 in a xenograft model
suggest that Ang1 may inhibit tumour growth, presumably via an
effect on tumour angiogenesis, as Ang1 had no effect on the in
vitro growth of the tumour cells. This is in keeping with the
hypothesized roles of Ang1 and its functional antagonist Ang2
(Maisonpierre et al, 1997) on vessel stability and receptivity to
other angiogenic influences. Ang1 stabilizes the association
between the endothelial cell and pericyte (Suri et al, 1996; 1998;
Thurston et al, 1999). Ang2, by antagonizing this effect, can result
in vessel disassembly and subsequent vessel regression, but may,
in the presence of other suitable angiogenic factors, facilitate new
vessel sprouting (Maisonpierre et al, 1997). It has recently been
observed that Ang2 is focally up-regulated in the immediate
vicinity of tumour vessels (Stratmann et al, 1998; Zagzag et al,
1999). Therefore in tumours, where a variety of other angiogenic
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Figure 5 Inhibition of MCF-7 human breast cancer xenograft tumour growth
by Ang1 overexpression. (A) Plots of tumour volumes of the xenograft
tumours formed by the MPCX parental cell line (closed circles), empty vector
transfected cells (closed squares), and three clones of Ang1 expressing
transfections: MAng 128 (open circles), MAng 166 (closed triangles), and
MAng 184 (open triangles). There were five animals per group. The
experiment was repeated and the results were reproducible. (B) The tumour
sizes as a function of time were fitted with an exponential tumour growth
model (see Methods) to determine the rate constants of the xenograft tumour
growth. Growth rates for the Ang1-overexpressing MPCX clones were
compared to that of the vector mock transfected cells (ANOVA)
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Figure 6 Inhibition of FGF1 transfected MCF-7 breast cancer xenograft
tumour growth by Ang1 overexpression. (A) Plots of tumour volumes of the
xenograft tumours formed by the α 18 parental cell line (closed circles), empty
vector transfected cells (closed squares), and three clones of Ang1
expressing transfectants: α Ang14 (open circles), α Ang18 (closed triangles),
and α Ang29 (open triangles). The overall statistical significance at 5% level
was P = 0.03 (ANOVA) (n=5) for α Ang18 and α Ang29. The experiment was
repeated and the results were reproducible. (B) Photographs of the xenograft
tumours: a tumour formed by α Ang14 giving the typical appearance of a
blood filled sac (left), cross-section of a tumour in the same group showing
that the interior of the sac is empty once opened, and that there are only a
few cancer cells which were stained blue (centre), and the tumour formed by
the parental α 18 cells consists of blue cancer cellsfactors exist, this stabilizing effect of Ang1 might in fact inhibit
the intense continuous new vessel sprouting that is typical of
tumour vascularization. That Ang1 is able to inhibit tumour
growth even in the presence of FGF1 supports the view that Ang1
retards tumour growth by vascular stabilization. Additionally, our
findings that Ang1 is expressed in many breast cancer cell lines in
vitro, but in very few clinical specimens, suggest that expression
of Ang1 may be down-regulated in tumours because of its nega-
tive selective effect on the developing tumour.
To identify the mechanism by which Ang1 may lead to retar-
dation of tumour growth requires a variety of further experi-
mental approaches. These may include a detailed histological
characterization of vessel branching and endothelial pericyte
relations in the Ang1 overexpressing tumours and a direct in situ
assessment of cellular proliferation rates within the xenografts
expressing Ang1. It will be informative to assess the expression
patterns of other ligands to Tie2 in clinical specimens, in partic-
ular Ang2. Such studies will further elucidate the role played 
by this complex vascular signalling pathway in the process of
tumour vascularization.
ACKNOWLEDGEMENTS
The authors thank Ms Mariella Tefft for assistance in statistical
analysis. Research is supported in part by a grant DAMD17-97-1-
7133 from the United States Department of Defence to LYL.
REFERENCES
Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, Yancopoulos
GD and Isner JM (1998) Tie2 receptor ligands, angiopoietin-1 and
angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ
Res 83: 233–240
Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig
M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L,
Collen D, Risau W and Nagy A (1996) Abnormal blood vessel development
and lethality in embryos lacking a single VEGF allele. Nature 380: 435–439
Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J,
Radziejewski C, Maisonpierre PC and Yancopoulos GD (1996) Isolation of
angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression
cloning. Cell 87: 1161–1169
de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N and Williams LT (1992) The
fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.
Science 255: 989–991
Dumont DJ, Gradwohl GJ, Fong GH, Auerbach R and Breitman ML (1993) The
endothelial-specific receptor tyrosine kinase, tek, is a member of a new
subfamily of receptors. Oncogene 8: 1293–1301
Dumont DJ, Fong GH, Puri MC, Gradwohl G, Alitalo K and Breitman ML (1995)
Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular
endothelial growth factor expression during development. Dev Dyn 203: 80–92
Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR,
Weiss RA and Liotta LA (1996) Laser capture microdissection. Science 274:
998–1001
Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O’Shea KS, Powell-Braxton
L, Hillan KJ and Moore MW (1996) Heterozygous embryonic lethality induced
by targeted inactivation of the VEGF gene. Nature 380: 439–442
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:
1182–1186
Hanahan D and Folkman J (1996) Patterns and emerging mechanisms of the
angiogenic switch during tumorigenesis. Cell 86: 353–364
Hayes AJ, Huang WQ, Mallah J, Yang D, Lippman ME and Li LY (1999)
Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like
tubule formation and survival of endothelial cells. Microvasc Res 58: 224–237
Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D,
Yancopoulos GD and Wiegand SJ (1999) Vessel cooption, regression, and
growth in tumors mediated by angiopoietins and VEGF. Science 284:
1994–1998
Koblizek TI, Weiss C, Yancopoulos GD, Deutsch U and Risau W (1998)
Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr Biol 8: 529–532
Kurebayashi J, McLeskey SW, Johnson MD, Lippman ME, Dickson RB and Kern
FG (1993) Quantitative demonstration of spontaneous metastasis by MCF-7
human breast cancer cells cotransfected with fibroblast growth factor 4 and
LacZ. Cancer Res 53: 2178–2187
Lehtola L, Partanen J, Sistonen L, Korhonen J, Warri A, Harkonen P, Clarke R and
Alitalo K (1992) Analysis of tyrosine kinase mRNAs including four FGF 
receptor mRNAs expressed in MCF-7 breast-cancer cells. Int J Cancer 50:
598–603
Maisonpierre PC, Goldfarb M, Yancopoulos GD and Gao G (1993) Distinct rat
genes with related profiles of expression define a TIE receptor tyrosine kinase
family. Oncogene 8: 1631–1637
Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C,
Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato
TN and Yancopoulos GD (1997) Angiopoietin-2, a natural antagonist for Tie2
that disrupts in vivo angiogenesis. Science 277: 55–60
McLeskey SW, Kurebayashi J, Honig SF, Zwiebel J, Lippman ME, Dickson RB and
Kern FG (1993) Fibroblast growth factor 4 transfection of MCF-7 cells
produces cell lines that are tumorigenic and metastatic in ovariectomized or
tamoxifen-treated athymic nude mice. Cancer Res 53: 2168–2177
McLeskey SW, Tobias CA, Vezza PR, Filie AC, Kern FG and Hanfelt J (1998)
Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells
correlates with density of specific microvessels independent of the transfected
angiogenic factor. Am J Pathol 153: 1993–2006
Papapetropoulos A, Garcia-Cardena G, Dengler TJ, Maisonpierre PC, Yancopoulos
GD and Sessa WC (1999) Direct actions of angiopoietin-1 on human
endothelium: evidence for network stabilization, cell survival, and interaction
with other angiogenic growth factors. Lab Invest 79: 213–223
Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse
R, Bicknell R and Harris AL (1997) Expression of the angiogenic factors
vascular endothelial cell growth factor, acidic and basic fibroblast growth
factor, tumor growth factor beta-1, platelet-derived endothelial cell growth
factor, placenta growth factor, and pleiotrophin in human primary breast cancer
and its relation to angiogenesis. Cancer Res 57: 963–969
Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-
Maguire M, Gridley T, Wolburg H, Risau W and Qin Y (1995) Distinct roles of
the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature
376: 70–74
Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML and
Schuh AC (1995) Failure of blood-island formation and vasculogenesis in Flk-
1-deficient mice. Nature 376: 62–66
Stratmann A, Risau W and Plate KH (1998) Cell type-specific expression of
angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis.
Am J Pathol 153: 1459–1466
Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN and
Yancopoulos GD (1996) Requisite role of angiopoietin-1, a ligand for the
TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171–1180
Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, Sato TN
and Yancopoulos GD (1998) Increased vascularization in mice overexpressing
angiopoietin-1. Science 282: 468–471
Takebe Y, Seiki M, Fujisawa J, Hoy P, Yokota K, Arai K, Yoshida M and Arai N
(1988) SR alpha promoter: an efficient and versatile mammalian cDNA
expression system composed of the simian virus 40 early promoter and the R-
U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol
Cell Biol 8: 466–472
Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC,
Gospodarowicz D and Bohlen P (1992) Identification of the KDR tyrosine
kinase as a receptor for vascular endothelial cell growth factor. Biochem
Biophys Res Commun 187: 1579–1586
Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD and McDonald
DM (1999) Leakage-resistant blood vessels in mice transgenically
overexpressing angiopoietin-1. Science 286: 2511–2514
Weidner N (1995) Current pathologic methods for measuring intratumoral
microvessel density within breast carcinoma and other solid tumors. Breast
Cancer Res Treat, 36: 169–180
Zagzag D, Hooper A, Friedlander DR, Chan W, Holash J, Wiegand SJ, Yancopoulos
GD and Grumet M (1999) In situ expression of angiopoietins in astrocytomas
identifies angiopoietin-2 as an early marker of tumor angiogenesis Exp Neurol
159: 391–400
Zhang L, Kharbanda S, Chen D, Bullocks J, Miller DL, Ding IY, Hanfelt J,
McLeskey SW and Kern FG (1997) MCF-7 breast carcinoma cells
overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized
or tamoxifen-treated nude mice. Oncogene 15: 2093–2108
1160 AJ Hayes et al
British Journal of Cancer (2000) 83(9), 1154–1160 © 2000 Cancer Research Campaign